Xbrane Biopharma Ab company information, Employees & Contact Information

XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE TradingView

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® Yahoo Finance

Xbrane Sees Strategic Opening For US Ranibizumab After Sandoz Withdrawal Citeline News & Insights

Xbrane Biopharma enters into conditional financing solution with Fenja Capital II A/S MarketScreener

Alvotech partnerships and acquisition: Dr Reddy’s, Advanz, Xbrane Generics and Biosimilars Initiative

Announcement from extra general meeting in Xbrane Biopharma AB TradingView

Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration Center for Biosimilars

OneSource collaborates with Xbrane Biopharma AB Business Standard

OneSource and Xbrane Biopharma announce strategic biosimilars manufacturing partnership for global markets BioSpectrum India

Investors Still Aren't Entirely Convinced By Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Despite 33% Price Jump simplywall.st

Record date for reverse share split in Xbrane Biopharma AB MarketScreener

Alvotech acquires Xbrane Generics and Biosimilars Initiative

Alvotech Acquires Xbrane’s R&D Operations in Sweden and GlobeNewswire

OneSource, Xbrane Partner for Global Biosimilar Supply Construction World India

CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets Center for Biosimilars

Announcement from extra general meeting in Xbrane Biopharma AB TradingView

Xbrane Biopharma (OM:XBRANE) Slides 6.7% After Reverse Split and Financing Ahead of FDA Decision – Has the Story Changed? Yahoo Finance

The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024 MarketScreener

Xbrane Biopharma Q2 2025 slides reveal Ximluci market share gains amid financial restructuring Investing.com

Earnings call transcript: Xbrane Biopharma Q3 2025 sees significant revenue miss Investing.com

Xbrane Biopharma Faces FDA Setback on Ranibizumab Biosimilar TipRanks

Xbrane Biopharma Reports Financial Turnaround Amid Regulatory Challenges TipRanks

Xbrane Biopharma Announces 2026 AGM Nomination Committee TipRanks

Xbrane Biopharma Secures Conditional Financing Amid FDA Approval Anticipation TipRanks

Xbrane Biopharma Restructures Share Capital and Authorizes New Issuances TipRanks

Redeye: Xbrane Biopharma Q1 2025 - Transformative times TradingView

Structure and function of the S. pombe III–IV–cyt c supercomplex PNAS

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2025 on October 24, 2025 TradingView

xBrane Biopharma | Generics | The Pharmaletter The Pharma Letter

Alvotech Expands Biosimilar Pipeline: Strategic $29M Acquisition Adds Cimzia Competitor Stock Titan

Xbrane and Intas to jointly develop Opdivo biosimilar The Pharma Letter

Xbrane Pulls In US Ranibizumab Partner After FDA Disappointment Citeline News & Insights

Advances for STADA-Xbrane’s Ximluci in Europe, the UK and the US Generics and Biosimilars Initiative

Xbrane Biopharma will be traded after the reverse stock split on October 17. MarketScreener

Xbrane Hails FDA Win On ‘Streamlined’ Nivolumab Trial Program Citeline News & Insights

Biosimilars Check-In: Celltrion Pushes for Yuflyma in Europe; Xbrane Updates on Ranibizumab Filing Center for Biosimilars

Xbrane submits FDA application for Ximluci Biostock

Xbrane Biopharma Trades Today on Nasdaq Stockholm Following 1: 125 Reverse Split MarketScreener

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane Business Standard

Biogen announces biosimilars collaboration deal with Xbrane drugdiscoverytrends.com

Xbrane Biopharma Faces FDA Setback on Ranibizumab Biosimilar MSN

Xbrane Biopharma Q3 2024 - Deal or no deal MarketScreener

OneSource Specialty Pharma and Xbrane Biopharma partner for commercial manufacturing of biosimilars MediaBrief

Production of Routine and Difficult Targets: Mary Ann Liebert, Inc.